A recent systematic review looked at the impact of different prices for infliximab in inflammatory bowel disease and the willingness-to-pay threshold around the world.
In recent years, Canada and other countries that require justifications for high-priced biologics have begun to shift patients to lower-cost biosimilars, known as nonmedical switching. Biosimilars for infliximab, used in inflammatory bowel disease (IBD), which encompasses Crohn disease (CD) and ulcerative colitis (UC), have become increasingly available.
The inclusion of biosimilars in economic evaluations for pricing decisions has been lacking, but researchers writing in MDM Policy & Access said that examining biologic drug price in a sensitivity analysis provided insight into the cost-effectiveness of biosimilar alternatives.
The authors screened studies using databases such as MEDLINE, Embase, Healthstar, Allied and Complementary Medicine, and more; economic assessments of infliximab for adult or pediatric CD and/or UC published from 1998 through 2019 where drug price was varied in sensitivity analysis were included. Eligible studies could include originator infliximab, biosimilar infliximab, or both, either as an exclusive comparator or used with other therapies; only economic evaluations that contained a 1-way sensitivity analysis of price could be included.
Researchers included each jurisidction’s stated willingness-to-pay threshold for the cost-effectiveness of infliximab.
Out of 844 studies screened, 31 were analyzed. Most studies (58%) showed an incremental cost-effectiveness of infliximab in gastrointestinal diseases that surpassed the WTP threshold.
However, infliximab showed favorable cost-effectiveness at a price ranging from C$66 (US$49) to C$1260 (US$930.13 per vial, depending on the location.
In many other countries, drugs are assessed for their therapeutic benefit relative to existing products, and depending on the outcome of that assessment, price ceilings are set accordingly.
But mandatory switching policies ordering the use of lower cost biosimilars in patients with IBD have incited worries for patients who prefer the original biologic.
The researchers of the current study said alternative pricing strategies and treatment access could be considered to allow patients with IBD to continue access to their current medications.
Reference
Bashir NS, Hughes A, Ungar WJ. Infliximab pricing in international economic evaluations in inflammatory bowel disease to inform biologic and biosimilar access policies: a systematic review. MDM Policy & Practice. Published online February 24, 2023.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.